Physician profile
Mary Audrey Ackerman
NPI 1912988536
$2,079.83
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,052 · 2020: $27.60.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $237.30 | 2019-2020 | |
| Amgen INC. | $186.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $172.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $167.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $160.53 | 2019 | |
| Genentech USA, INC. | $157.56 | 2019 | |
| Merck Sharp & Dohme LLC | $141.35 | 2019 | |
| Incyte Corporation | $82.62 | 2019 | |
| Astellas Pharma US INC | $81.35 | 2019 | |
| Janssen Biotech, INC. | $64.70 | 2019-2020 | |
| Celgene Corporation | $58.23 | 2019 | |
| Puma Biotechnology, INC. | $51.50 | 2019 | |
| Lilly USA, LLC | $47.69 | 2019 | |
| Clovis Oncology, INC. | $46.62 | 2019 | |
| Gilead Sciences, INC. | $45.36 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $38.09 | 2019 | |
| Eisai INC. | $37.12 | 2019 | |
| Aurobindo Pharma USA, INC. | $33.50 | 2019 | |
| Seagen INC. | $28.27 | 2019 | |
| Daiichi Sankyo INC. | $28.03 | 2019 | |
| Kyowa Kirin, INC. | $24.44 | 2019 | |
| Abbvie INC. | $24.38 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $22.90 | 2019 | |
| Taiho Oncology, INC. | $22.39 | 2019 | |
| Pfizer INC. | $22.20 | 2019 | |
| Emd Serono, INC. | $20.58 | 2019 | |
| Genzyme Corporation | $19.89 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.16 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.10 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.21 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $11.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Audrey Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.